These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 34149732)

  • 1. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells.
    Cui Y; Cai J; Wang W; Wang S
    Front Immunol; 2021; 12():690207. PubMed ID: 34149732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histone deacetylase inhibitors: highlight on epigenetic regulation].
    Pécuchet N; Cluzeau T; Thibault C; Mounier N; Vignot S
    Bull Cancer; 2010 Aug; 97(8):917-35. PubMed ID: 20483706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current evidence for histone deacetylase inhibitors in pancreatic cancer.
    Koutsounas I; Giaginis C; Patsouris E; Theocharis S
    World J Gastroenterol; 2013 Feb; 19(6):813-28. PubMed ID: 23430136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.
    Adeshakin AO; Adeshakin FO; Yan D; Wan X
    Front Immunol; 2022; 13():781660. PubMed ID: 35140716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors: insights into mechanisms of lethality.
    Rosato RR; Grant S
    Expert Opin Ther Targets; 2005 Aug; 9(4):809-24. PubMed ID: 16083344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors.
    Huang M; Geng M
    Sci China Life Sci; 2017 Jan; 60(1):94-97. PubMed ID: 27888384
    [No Abstract]   [Full Text] [Related]  

  • 12. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential.
    Zhang C; Li HX; Man Y; Jiang ZH; Yin P; Yu K
    J Physiol Pharmacol; 2024 Apr; 75(2):117-122. PubMed ID: 38736259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of HDACs--effective drugs against cancer?
    Müller S; Krämer OH
    Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
    Salek Farrokhi A; Mohammadlou M; Abdollahi M; Eslami M; Yousefi B
    J Gastrointest Cancer; 2020 Sep; 51(3):754-764. PubMed ID: 31808058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
    Petta V; Gkiozos I; Strimpakos A; Syrigos K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors: anticancer compounds.
    Smith KT; Workman JL
    Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
    Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C
    Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.